CSF3 and plasma cell myeloma: In this sense, AMD3100 is administered in combination with the granulocyte-colony-stimulating factor (G-CSF) to enhance HSPCs mobilization for autologous transplantation in patients with lymphoma or multiple myeloma [155, 156] and children with lymphoma or solid tumors [157, 158].